School of Life Sciences and the State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, China.
Changzhou High-Tech Research Institute of Nanjing University and Jiangsu TargetPharma Laboratories Inc, Changzhou, China.
J Cell Biochem. 2019 Aug;120(8):14017-14027. doi: 10.1002/jcb.28676. Epub 2019 Apr 7.
In this study, we explored the therapeutic potential of microRNA (miR) analogs against non-small-cell lung cancer (NSCLC) using lentiviral delivery of short hairpin RNA (shRNA). By using A549 as a model cell line, we used analogs and mimics of miR-4319/miR-125-5p to target the tumorigenic RAF1 gene. Lentiviral vectors carrying shRNA of a highly efficient miRNA analog of miR-4319/miR-125-5p, Analog2, were constructed to infect A549 cells. Our results showed that, compared with the noncancerous bronchial epithelial cell line 16HBE, lentivirus delivering Analog2 shRNA induced significant G2/M arrest and subsequent apoptosis in A549 cells, but not in 16HBE cells. Western blot analysis revealed that key factors regulating cell cycle were downregulated following RAF1 inhibition. In vivo xenograft experiments showed that lentivirus carrying Analog2 shRNA markedly decreased tumor size. Therefore, lentiviral delivery of Analog2 shRNA is a valid RNA interference-based treatment against NSCLC with high potency and specificity.
在这项研究中,我们使用慢病毒递送短发夹 RNA(shRNA)来探索 microRNA(miRNA)类似物对非小细胞肺癌(NSCLC)的治疗潜力。我们使用 A549 作为模型细胞系,使用 miR-4319/miR-125-5p 的类似物和模拟物来靶向致癌 RAF1 基因。构建了携带 miR-4319/miR-125-5p 高效 miRNA 类似物 Analog2 的 shRNA 的慢病毒载体来感染 A549 细胞。我们的结果表明,与非癌性支气管上皮细胞系 16HBE 相比,递送 Analog2 shRNA 的慢病毒在 A549 细胞中诱导明显的 G2/M 期阻滞和随后的细胞凋亡,但在 16HBE 细胞中没有。Western blot 分析显示,RAF1 抑制后,调节细胞周期的关键因子下调。体内异种移植实验表明,携带 Analog2 shRNA 的慢病毒显著降低了肿瘤大小。因此,慢病毒递送 Analog2 shRNA 是一种针对 NSCLC 的有效 RNA 干扰治疗方法,具有高效性和特异性。